Article Text
Abstract
Introduction/Background Cervical intraepithelial neoplasia is a precancerous lesion of the cervix which is at risk of progressing to cervical cancer. Precancerous cervical lesions are classified based on the histological changes they present. In CIN II abnormal histological changes affect 1/3 to 2/3 of the cervical epithelium.
Low grade lesions (CIN I )have slow progression, high grade lesions (CIN II, CIN III) have faster progression to cervical cancer. CIN2 is typically treated. But some studies have suggested that CIN2 lesions often regress completely without treatment and should therefore be simply monitored instead. Treating these lesions can pose a risk to future pregnancies.
The aim of the study is to study the course of untreated CIN II, for a period of 6 months, in women aged 25–35 years, which constitute the age group with the highest birth rate.
Methodology This study is retrospective and analyzes the progression of CIN II in 70 patients at ’Queen Geraldine’ University Hospital, which met the following criteria: a) histological diagnosis with CIN II at the first visit, b) age group 25–35 years at the first visit, c) in which no therapy was applied in the last 6 months from the diagnosis, ç) which had done at least one follow-up visit after diagnosis, d) who were not pregnant at the time of diagnosis, e) for the period 2015–2020
Results Only 31 women met all the criteria set above.
14 (45%) patients had spontaneous regression,
12 (39%) patients had no changes while 5 (16%) patients progressed to CIN III.
Conclusion CIN II and III are high-grade lesions but differ from each other in terms of oncogenic potential. Treatment of high-grade lesions is done through excision or destruction of the transformation zone.
Disclosures Treatment for CIN 2 may include cryotherapy, laser therapy, loop electrosurgical procedure (LEEP), or cone biopsy to remove or destroy the abnormal tissue.This treatment has a risk of intraoperative hemorrhage and premature birth in future pregnancies, should therefore evaluate the benefits and risks of treatment.